Pricing and reimbursement solutions for high-cost combination therapies
The scale and potential impact of high-cost combinations coming to market in the next 2–3 years will force a significant change in pricing and reimbursement policies.
European advisors met with PRMA Consulting to provide unique, targeted market access insights into the challenges of pricing combination therapies, and to discuss effective strategies for market access success.
This market access paper explores:
- the challenges for pricing and market access associated with high-cost combination therapies
- three potential market access strategies for demonstrating value for combination therapies.